Argenx halts late-stage Sjogren’s trial of Vyvgart
Argenx stopped a late-stage clinical trial of Vyvgart for Sjogren's disease due to lack of efficacy, with shares down 18% in European morning trading.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.